Michael Makris/LinkedIn
Nov 19, 2025, 02:49
Michael Makris: Novo Nordisk has Decided to Discontinue Their Haemophilia A Gene Editing Program
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
“Novo Nordisk has decided to discontinue their haemophilia A gene editing program.
Novo Nordisk have had concizumab approved recently, and I expect their bispecific Mim8 to be approved soon. I expect this had a major impact on the decision to discontinue the gene editing program.”
Stay updated with Hemostasis Today.
-
May 27, 2026, 23:00Octavio Marques Pontes-Neto: Exchanging Latin American Experiences at the Global Stroke Alliance Meeting in Buenos Aires
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?
-
May 27, 2026, 17:09Yvonne Jongejan: Allele-Selective Silencing Therapy for VWD and Thrombotic Disorders
-
May 27, 2026, 16:58Catherine Moran: Important Step Forward as 1st WHO Resolution on Stroke Gets Adopted at WHA79
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care